Project Grant R01AI182232
Award Date
12/6/24
Completion Date
11/30/29
Dollars Obligated
$691K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02118, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $813,160 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The goal is to create vaccines that provide effective immune protection against malaria infection and reduce disease transmission. The project will evaluate protective efficacy of...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award, totaling $708,202 and effective from December 2024 through November 2029, will support research at Brown University to identify the parasite...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $479,204 to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The research aims to identify parasite genes associated with severe disease, which could inform vaccine and drug development. Key aspects include: Sequencing variant surface antigen transcripts...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $520,809 in funding to Rosalind Franklin University of Medicine & Science over the period from September 5, 2024 to August 31, 2029. The overarching goal of this research project is to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, such as malaria....
This federal Project Grant award, with a total funding amount of $1,553,810, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop a genomic surveillance approach to identify mutations under selection in functional pathways associated with artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The key objectives are to: 1) identify parasite loci...
This Project Grant award, valued at $1,104,050 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the molecular mechanisms by which Plasmodium falciparum's secreted histidine-rich protein II (HRPII) impairs neutrophil function and oxidative burst activity. The research, conducted by The Washington University, will utilize targeted molecular blockade and unbiased...
The federal Project Grant award of $700,288 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to identify genetic factors associated with the development of sexual stages (gametocytes) in the malaria parasite Plasmodium falciparum. The project combines expertise in gametocyte biology, advanced computational genomics, and phenotype comparisons with clinical...
This Project Grant award of $375,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research by the University of South Florida to study the function of messenger ribonucleoprotein (mRNP) granules in regulating RNA metabolism in the malaria parasite Plasmodium falciparum. The researchers aim to identify molecular markers for distinct mRNP types, determine their protein and mRNA...